Alzheimer's disease (AD) threatens to bankrupt United States medical care system. As the United States demographics ages, AD will grow exponentially and become a pandemic with more than 16 million people, the current population of New York City, Los Angeles, Chicago, and Houston, combined, living with the disease by 2050. The long--term and the intensive around-the clock custodial care required for AD patients is inordinately expensive with current United States and world-wide costs estimated at more than $148 billion and $315.4 billion annually, respectively. A new drug, which merely delays the onset of new Alzheimer's disease cases for 5 years between 2010 and 2050, would yield a $4 trillion per year societal benefit. Unfortunately, there currently is no drug that comes anywhere close to providing such a delay. With no proven treatment as a guide, the best hope for finding a disease-modifying therapy is to take as many different "shots on goal" in clinical trials as soon as possible to find a treatment that "scores." This grant advances a "first in class" AD therapeutic through the Food and Drug Administration clearance, the first step towards clinical trials. The compound is a potentially disease modifying therapy that may delay, or possibly reverse, the cognitive decline caused by AD. Moreover, the compound has been previously shown safe to use in man. As such, this grant may ultimately result in a new therapy that reduces the financial cost of AD on the medical system and lightens the heavy burden carried by afflicted families. At a minimum, the grant will provide some hope to those that currently have very little.